Table 1.

Progression-free survival in HER2-positive metastatic breast cancer

Patient subgroup	T-DXd	T-DM1	HR (95% CI)
All patients (N = 524)	Not reached	6.8 months	0.28 (0.22-0.37)
Hormone receptor status
Positive (n = 272)	22.4 months	6.9 months	0.32 (0.22-0.46)
Negative (n = 248)	Not reached	6.8 months	0.30 (0.20-0.44)
Prior pertuzumab treatment
Yes (n = 320)	Not reached	6.8 months	0.32 (0.22-0.46)
No (n = 204)	Not reached	7.0 months	0.30 (0.19-0.47)
Prior lines of therapy
0-1 (n = 258)	22.4 months	8.0 months	0.33 (0.23-0.48)
≥2 (n = 266)	Not reached	5.6 months	0.28 (0.19-0.41)
Visceral metastases
Yes (n = 384)	22.2 months	5.7 months	0.28 (0.21-0.38)
No (n = 140)	Not reached	11.3 months	0.32 (0.17-0.58)
Brain metastases
Yes (n = 82)	15.0 months	3.0 months	0.25 (0.13-0.45)
No (n = 442)	Not reached	7.1 months	0.32 (0.22-0.40)

Abbreviations: CI, confidence interval; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.